MedTrace Logo

Thrombin Generation as a New Test for Anticoagulation Management in Patients With ECMO

NCT03832842 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2021-02-04

No results posted yet for this study

Summary

ECMO (Extracorporeal Membrane Oxygenation) is a circulatory assistance device aiming at maintaining or restoring cardiopulmonary circulation. Complications of this device are mainly hemorrhagic, related to coagulopathy induced by the initial pathology or by the device itself, or thrombotic and ischemic. One of the major challenges is therefore the management of a suitable curative anticoagulation, sufficient to limit the activation of hemostasis du to the ECMO, but reasonable to prevent hemorrhagic complications. To date, there is no standardized and validated protocol for the management of anticoagulation of patients under ECMO. The thrombin generation may be a valuable test to manage anticoagulation of patients with ECMO.

Conditions

  • Implantation of a Veno-arterial or Veno-venous ECMO

Interventions

DIAGNOSTIC_TEST

Blood sample

Blood sample

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    lead OTHER

Principal Investigators

  • Julie HELMS, MD, PhD · University Hospital, Strasbourg, France

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-16
Primary Completion
2020-12-04
Completion
2021-02-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03832842 on ClinicalTrials.gov